SciELO - Scientific Electronic Library Online

 
vol.30 issue1Nomenclature evolution for factors of human leukocyte antigen systemImmunophenotypic characterization of patients with acute myeloid leukemia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Hematología, Inmunología y Hemoterapia

Print version ISSN 0864-0289

Abstract

MACHIN-GARCIA, Sergio et al. Moderate dose of hydroxyurea in children with sickle cell disease and stroke. Preliminary results. Rev Cubana Hematol Inmunol Hemoter [online]. 2014, vol.30, n.1, pp. 21-26. ISSN 0864-0289.

Twenty children with sickle cell anemia, two with SC hemoglobinopathy and one with S/â0 thalassemia were treated, with a previous stroke or abnormal ultrasound transcranial Doppler (TCD) flow velocities more than 170 cm/s. The mean follow-up was of 41 ± 19 months. Hydroxyurea (HU) at a dose of 25 mg/kg/day associated with chronic transfusion therapy, was administrated during one year to patients with stroke. Patients with abnormal TCD received only HU at the same dose. There was a significant decrease of stroke (p <0.02) and TCD flow velocities in the right middle cerebral artery (p <0.003). It was necessary to associate chronic transfusion therapy in three children with high velocities in TCD without stroke, due to the lack of response to the treatment with HU. The combination of HU and transfusions during one year can be useful for stroke therapy and prevention.

Keywords : sickle cell disease; stroke; hydroxyurea; chronic transfusion.

        · abstract in Spanish     · text in English     · English ( pdf )